HURA vs. META

Last updated Apr 1, 2026

Compare and contrast key facts about TuHURA Biosciences, Inc. (HURA) and Meta Platforms, Inc. (META).

Performance

HURA vs. META - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in TuHURA Biosciences, Inc. (HURA) and Meta Platforms, Inc. (META). The values are adjusted to include any dividend payments, if applicable.

HURA vs. META - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
HURA TuHURA Biosciences, Inc.	136.55%	-81.50%	-31.10%	-97.54%	-72.98%	-60.16%	85.51%	-79.82%	-68.63%	-65.82%
META Meta Platforms, Inc.	-13.25%	13.09%	66.05%	194.13%	-64.22%	23.13%	33.09%	56.57%	-25.71%	53.38%

Fundamentals

EPS HURA : -$0.62 META : $23.51
Total Revenue (TTM) HURA : $0.00 META : $200.97B
Gross Profit (TTM) HURA : -$17.64K META : $164.79B
EBITDA (TTM) HURA : -$28.68M META : $104.55B

Returns By Period

In the year-to-date period, HURA achieves a 136.55% return, which is significantly higher than META's -13.25% return. Over the past 10 years, HURA has underperformed META with an annualized return of -65.23%, while META has yielded a comparatively higher 17.39% annualized return.

HURA

• 1D: 3.47%
• 1M: 7.19%
• YTD: 136.55%
• 6M: -27.82%
• 1Y: -44.58%
• 3Y*: -75.62%
• 5Y*: -77.66%
• 10Y*: -65.23%

META

• 1D: 6.67%
• 1M: -11.66%
• YTD: -13.25%
• 6M: -21.96%
• 1Y: -0.42%
• 3Y*: 39.60%
• 5Y*: 14.06%
• 10Y*: 17.39%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

HURA vs. META — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

HURA

HURA Risk / Return Rank: 29
HURA Sharpe Ratio Rank: 25
HURA Sortino Ratio Rank: 36
HURA Omega Ratio Rank: 35
HURA Calmar Ratio Rank: 24
HURA Martin Ratio Rank: 25

META

META Risk / Return Rank: 40
META Sharpe Ratio Rank: 41
META Sortino Ratio Rank: 38
META Omega Ratio Rank: 37
META Calmar Ratio Rank: 42
META Martin Ratio Rank: 41

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

HURA vs. META - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for TuHURA Biosciences, Inc. (HURA) and Meta Platforms, Inc. (META). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	HURA	META	Difference
Sharpe ratio Return per unit of total volatility	-0.35	-0.01	-0.34
Sortino ratio Return per unit of downside risk	0.24	0.29	-0.05
Omega ratio Gain probability vs. loss probability	1.03	1.04	-0.01
Calmar ratio Return relative to maximum drawdown	-0.55	-0.01	-0.54
Martin ratio Return relative to average drawdown	-0.97	-0.04	-0.93
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

HURA vs. META - Sharpe Ratio Comparison

The current HURA Sharpe Ratio is -0.35, which is lower than the META Sharpe Ratio of -0.01. The chart below compares the historical Sharpe Ratios of HURA and META, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	HURA	META	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.35	-0.01	-0.34
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.56	0.32	-0.88
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.51	0.45	-0.97
Sharpe Ratio (All Time) Calculated using the full available price history	-0.46	0.55	-1.01

Correlation

The correlation between HURA and META is 0.10, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

HURA vs. META - Dividend Comparison

HURA has not paid dividends to shareholders, while META's dividend yield for the trailing twelve months is around 0.37%.

	TTM	2025	2024
HURA TuHURA Biosciences, Inc.	0.00%	0.00%	0.00%
META Meta Platforms, Inc.	0.37%	0.32%	0.34%

Drawdowns

HURA vs. META - Drawdown Comparison

The maximum HURA drawdown since its inception was -100.00%, which is greater than META's maximum drawdown of -76.74%. Use the drawdown chart below to compare losses from any high point for HURA and META.

Drawdown Indicators

	HURA	META	Difference
Max Drawdown Largest peak-to-trough decline	-100.00%	-76.74%	-23.26%
Max Drawdown (1Y) Largest decline over 1 year	-89.60%	-33.30%	-56.30%
Max Drawdown (5Y) Largest decline over 5 years	-99.99%	-76.74%	-23.25%
Max Drawdown (10Y) Largest decline over 10 years	-100.00%	-76.74%	-23.26%
Current Drawdown Current decline from peak	-100.00%	-27.41%	-72.59%
Average Drawdown Average peak-to-trough decline	-88.16%	-15.19%	-72.97%
Ulcer Index Depth and duration of drawdowns from previous peaks	50.98%	13.13%	+37.85%

Volatility

HURA vs. META - Volatility Comparison

TuHURA Biosciences, Inc. (HURA) has a higher volatility of 28.24% compared to Meta Platforms, Inc. (META) at 13.64%. This indicates that HURA's price experiences larger fluctuations and is considered to be riskier than META based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	HURA	META	Difference
Volatility (1M) Calculated over the trailing 1-month period	28.24%	13.64%	+14.60%
Volatility (6M) Calculated over the trailing 6-month period	105.26%	26.73%	+78.53%
Volatility (1Y) Calculated over the trailing 1-year period	128.59%	39.91%	+88.68%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	139.29%	43.77%	+95.52%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	127.70%	38.46%	+89.24%

Financials